Lion Point Capital’s Spyre Therapeutics SYRE Stock Holding History

Lion Point Capital’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-12,000	Closed	-$1.43M	–	46
2022 Q2	$1.43M	Hold	12,000	–	–	0.16%	35
2022 Q1	$690K	Hold	12,000	–	–	0.16%	29
2021 Q4	$1.43M	Hold	12,000	–	–	0.38%	27
2021 Q3	$2.38M	Hold	12,000	–	–	0.45%	28
2021 Q2	$2.09M	Hold	12,000	–	–	0.36%	28
2021 Q1	$2.38M	Hold	12,000	–	–	0.43%	24
2020 Q4	$2.36M	Hold	12,000	–	–	0.45%	20
2020 Q3	$2.13M	Hold	12,000	–	–	0.47%	21
2020 Q2	$2.77M	Buy	+12,000	New	+$2.29M	0.67%	21

Other funds holding SYRE

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Lion Point Capital's SYRE Position: Q3 2022 in Review

Lion Point Capital sold out of Spyre Therapeutics (SYRE) in Q3 2022, closing a stake of 12,000 shares — an estimated $1.43M sold.

Lion Point Capital first reported a position in SYRE in Q2 2020 and held it in 9 quarters. The position peaked at $2.77M in Q2 2020. 55 funds tracked by Wall St. Rank hold SYRE as of Q3 2022.

Lion Point Capital reported no remaining Spyre Therapeutics position as of Q3 2022 after selling out during the quarter.
Lion Point Capital sold 12,000 Spyre Therapeutics shares in Q3 2022, an estimated $1.43M.
Lion Point Capital first reported a position in Spyre Therapeutics in Q2 2020 and held it in 9 quarters.
Lion Point Capital's Spyre Therapeutics position peaked at $2.77M in Q2 2020.
55 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2022.

Based on Lion Point Capital's 13F filing for Q3 2022, filed 14 Nov 2022.